What is the drug of choice for pseudomembranous colitis (Clostridioides difficile infection) in adults?

Drug of Choice for Pseudomembranous Colitis

Oral vancomycin 125 mg four times daily for 10 days or fidaxomicin 200 mg twice daily for 10 days are the first-line drugs of choice for any initial episode of Clostridioides difficile infection (pseudomembranous colitis), regardless of disease severity. 1, 2

First-Line Treatment for Initial Episodes

The 2017 IDSA/SHEA guidelines explicitly recommend either vancomycin or fidaxomicin as first-line therapy for all initial CDI episodes, replacing the previous severity-based approach that used metronidazole for mild disease. 1, 2

• Vancomycin 125 mg orally four times daily for 10 days is the standard regimen with strong recommendation and high-quality evidence. 1, 2
• Fidaxomicin 200 mg orally twice daily for 10 days is equally effective for initial cure (88-92% vs. 86-90% with vancomycin) but superior in preventing recurrence (13-15% vs. 24-25% with vancomycin). 3, 4, 5
• When cost is not limiting, fidaxomicin is preferred because it reduces recurrence rates by approximately 40% compared to vancomycin. 2, 4

Metronidazole: No Longer First-Line

Metronidazole 500 mg three times daily for 10 days should only be used when vancomycin and fidaxomicin are unavailable, as it has inferior cure rates, particularly in severe disease (76% vs. 97% with vancomycin). 1, 2, 6

• Repeated metronidazole courses must be avoided due to cumulative, potentially irreversible neurotoxicity (peripheral neuropathy, ataxia, confusion, seizures). 1, 2, 7
• The shift away from metronidazole reflects both its lower efficacy and safety concerns with prolonged use. 2, 6

Severity-Specific Modifications

Non-Severe Disease (WBC ≤15,000/µL and creatinine <1.5 mg/dL)

• Use the same standard vancomycin or fidaxomicin regimen; no dose adjustment needed. 1, 2

Severe Disease (WBC ≥15,000/µL or creatinine ≥1.5 mg/dL)

• The same 125 mg vancomycin dose four times daily is recommended; higher doses provide no additional benefit for non-fulminant severe disease. 1, 2
• Fidaxomicin 200 mg twice daily remains equally appropriate. 1, 2

Fulminant Disease (hypotension/shock, ileus, or megacolon)

This is a medical emergency requiring aggressive multi-route therapy:

• High-dose oral vancomycin 500 mg four times daily (via mouth or nasogastric tube). 1, 2
• Add rectal vancomycin 500 mg in 100 mL normal saline every 6 hours as a retention enema when ileus is present. 1, 2
• Add intravenous metronidazole 500 mg every 8 hours concurrently to ensure colonic drug levels when oral delivery is compromised by ileus. 1, 2, 8

Treatment Duration

• A standard 10-day course is recommended for all initial episodes. 1, 2
• Extension to 14 days may be considered when clinical response is delayed, particularly after escalation from metronidazole to vancomycin. 1, 2

Management of Recurrences

First Recurrence

• If metronidazole was used initially: switch to vancomycin 125 mg four times daily for 10 days. 1, 2
• If standard vancomycin was used initially: employ a tapered-and-pulsed vancomycin regimen (125 mg qid for 10-14 days, then bid for 7 days, then daily for 7 days, then every 2-3 days for 2-8 weeks; total 6-11 weeks). 1, 2, 9
• Alternative: fidaxomicin 200 mg twice daily for 10 days, which reduces second recurrence risk (19.7% vs. 35.5% with vancomycin). 2, 5

Second or Subsequent Recurrences

• Continue tapered-and-pulsed vancomycin as above. 1, 2
• Sequential therapy: vancomycin 125 mg qid for 10 days followed by rifaximin 400 mg three times daily for 20 days. 1, 2
• Fecal microbiota transplantation (FMT) is recommended after failure of at least two appropriate antibiotic courses (i.e., after three total CDI episodes). 1, 2

Critical Pitfalls to Avoid

• Never use intravenous vancomycin alone for CDI; it does not achieve therapeutic colonic concentrations. 2
• Avoid antiperistaltic agents (loperamide, diphenoxylate) and opioid analgesics in active CDI, as they worsen outcomes and increase complications. 2
• Do not perform a "test of cure" after therapy completion; clinical response within 3-5 days is the appropriate endpoint. 2
• Discontinue the inciting antibiotic immediately when clinically feasible, as this is the most important modifiable factor to reduce recurrence and treatment failure. 2
• Do not use high-dose vancomycin (500 mg qid) for non-fulminant disease; the standard 125 mg dose already exceeds the MIC90 for C. difficile by several orders of magnitude. 2